CD4 and cranioectodermal dysplasia: As an intriguing example, taking advantage of the identified disease-inducing gluten-derived epitopes in patients with CeD [12], Nexvax2 was designed as a peptide-based, epitope-specific therapeutic vaccine aimed at inducing CD4+ T tolerance towards dietary gluten and preventing the relapse of the disease after gluten consumption in patients with CeD.